Showing results (261-270 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|October 17, 2017
Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trialsNicole U Stoffel, Colin I Cercamondi, Gary Brittenham, et al.
The Lancet. Haematology|January 6, 2018
Epidemiological patterns of leukaemia in 184 countries: a population-based studyAdalberto Miranda-Filho, Marion Piñeros, Jacques Ferlay, et al.
The Lancet. Haematology|October 22, 2020
The effect of blood transfusion on outcomes among African children admitted to hospital with Plasmodium falciparum malaria: a prospective, multicentre observational studyHans Ackerman, Aintzane Ayestaran, Christopher H O Olola, et al.
The Lancet. Haematology|October 22, 2020
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysisTheodora Anagnostou, Irbaz B Riaz, Shahrukh K Hashmi, et al.
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.
The Lancet. Haematology|September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.
The Lancet. Haematology|June 25, 2021
Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemiaLiv Andrés-Jensen, Andishe Attarbaschi, Edit Bardi, et al.
The Lancet. Haematology|June 30, 2022
Associations between non-anaemic iron deficiency and outcomes following elective cardiac surgery (IDOCS): a prospective cohort studyLachlan F Miles, Vanessa Pac Soo, Sabine Braat, et al.
The Lancet. Haematology|May 28, 2021
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trialDavid J Straus, Monika Długosz-Danecka, Joseph M Connors, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
Pageof 73